Pernix Therapeutics Revenue, Profits - PTX Quarterly Income Statement

Add to My Stocks
$2.42 $0.07 (2.81%) PTX stock closing price Mar 23, 2018 (Closing)

PTX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Pernix Therapeutics stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from 34.32M to 40.47M and how operating and non operating activities have impacted the PTX stock. Revenue for year 2017 Q3 is $40.47M and has increased from $34.32M quarter on quarter as is evident when you compare the latest figures in the latest Pernix Therapeutics profit and loss statement with those of the prior corresponding period. Also see Pernix Therapeutics assets and Pernix Therapeutics free cash flow for a complete valuation of PTX stock.

View and download details of revenue and profits for Pernix Therapeutics for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Pernix Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)10.58M10.49M10.04M9.06M10.84M12.19M11.23M14.51M12.03M
Pernix Therapeutics Gross Profit
Research & Development Expense----1.71M2.49M-2.58M3.18M
Selling General & Admin Expense10.56M18.16M20.72M76.3M25.61M23.29M20.44M51.93M23.81M
Income Before Depreciation Depletion Amortization19.22M5.57M-1.54M-56.11M3.29M-1.23M-0.14M-22.62M9.58M
Depreciation Depletion Amortization18.21M18.21M18.54M20.71M20.7M21.06M23.66M28.21M25.73M
Non Operating Income14.69M--0.35M2.19M-0.17M-6.93M-0.67M9.45M
Interest Expense9.32M9.2M8.95M11.05M8.85M8.93M9.02M9.28M9.68M
Pernix Therapeutics Pretax Income
Provision for Income Taxes------0.01M-20.87M-5.64M
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations6.36M-21.62M-29.46M-86.08M-26.44M-31.14M-25.94M-81.67M-10.74M
Extraordinary Items & Discontinued Operations---------
Pernix Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS16.52M10.02M10.02M7.83M8.84M6.67M6.11M6.11M6M
Average Shares used to compute Basic EPS11.12M10.02M10.02M7.83M8.84M6.67M6.11M6.11M6.1M
Income Before Nonrecurring Items-9.97M-21.62M-29.46M-37.21M-24.16M-32.57M-21.52M-36.01M5.04M
Income from Nonrecurring Items16.33M---48.87M-2.28M1.43M-4.42M-45.66M-15.78M
Pernix Therapeutics Earnings Per Share Basic Net
Pernix Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.57-2.16-2.94-3.86-2.73-4.90-3.50-5.900.80
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Pernix Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $40.47M for this quarter of 2017 Q3. Our Pernix Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $6.36M for Pernix Therapeutics for 2017 Q3. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the PTX income statement, one can check the Pernix Therapeutics historical stock prices to check how the price has moved with time.

Pernix Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield